We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fast Triple Test a Game Changer for Expectant Mothers

By LabMedica International staff writers
Posted on 24 Jul 2025

HIV/AIDS, Hepatitis B, and Syphilis continue to pose significant health threats across Africa, especially among pregnant women. More...

Testing for these infections is often fragmented and time-consuming, with Syphilis testing rates lagging behind those for HIV and Hepatitis B. In Rwanda, for example, while testing coverage exceeds 95% for HIV and Hepatitis B, Syphilis testing remains under 70% due to being offered separately. In Kenya, a study revealed that 95.3% of surveyed women had never been tested before, pointing to limited access to screening services. Prevalent stockouts of testing kits and reagents further exacerbate the problem, hindering timely and comprehensive diagnostics. Now, a single test that allows for the simultaneous detection of the three infections is expected to reduce the time patients spend in healthcare facilities and improve the efficiency of healthcare delivery across Africa.

Abbott (Abbott Park, IL, USA) has introduced the WHO-approved Determine Antenatal Care Panel (ANC Panel), a triple test kit that requires only a single finger prick and delivers results within 20 minutes. The development was guided by efforts to eliminate HIV/AIDS, Hepatitis B, and Syphilis by 2030 and improve healthcare efficiency across Africa. The ANC Panel combines the testing for all three infections into a single, streamlined process. The kit is expected to cut the average clinic visit time from 113 minutes to 39 minutes and ease the workload of healthcare staff. In Kenya, where the kit was evaluated, it significantly reduced wait times and improved access to care. Despite initial challenges in hepatitis testing compared to malaria, the ANC Panel demonstrated high accuracy and usability.

In the Kenyan study, 95% of women rated the triple test kit as reliable and accurate, underscoring its potential to improve diagnostics. Officials in Rwanda confirmed that the test aligns with national goals and ongoing triple elimination strategies. Though the test is currently targeted at women, it has also been used to test men in Kenya, and Rwandan authorities are exploring a similar inclusive approach. The rollout is expected to begin across several countries based on available funding and interest. Discussions with global partners are ongoing to support broader deployment. The ANC Panel may soon serve not just antenatal care, but also contribute to broader screening efforts among diverse populations.

Related Links:
Abbott


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.